key: cord-0820692-vh3opnaj
authors: Moeckli, Beat; Peloso, Andrea; Oldani, Graziano; Orci, Lorenzo A.; Banz, Vanessa; Dutkowski, Philipp; Toso, Christian; Berney, Thierry
title: The Swiss approach to the COVID‐19 outbreak
date: 2020-04-24
journal: Am J Transplant
DOI: 10.1111/ajt.15939
sha: fc51e19c81d30b173fbb65fbcce988a59db3ff4e
doc_id: 820692
cord_uid: vh3opnaj

Angelico et al. described the impact of the novel coronavirus (COVID‐19) outbreak on organ transplantation in Italy (1), where only one center in Milan has limited transplant activity to most urgent cases. The rest of the country continued with the regular allocation policy (1). In Switzerland, which has more COVID‐19 cases per capita than Italy (2), we have opted for a stepwise approach.

In Geneva, a regional hotspot (2), we halted all transplantation activity, except for urgent cases (level 5). Less affected centers have continued their activity at level 4 (Table 1) 

This article is protected by copyright. All rights reserved This development is concerning on two levels. Firstly, the increase in waiting time will likely increase the waitlist mortality after the pandemic. This raises the question whether it is ethical to trade-off immediate COVID-19-related mortality for a projected increase in waitlist mortality.

Jeopardizing the survival of patients on the waiting list cannot be an acceptable long-term option but might be inevitable in the short-term. In extreme situations, requiring triage of resources, delaying access to a life-saving organ is also a triage decision. However, a staged resumption of transplantation activity, once the pandemic has reached a plateau, is essential. Secondly, in a setting where transplantation activity is significantly reduced, patients with a Model End Stage Liver Disease (MELD) exception will inevitably gain points merely by waiting. It is crucial to avoid putting patients with a true laboratory MELD at a disadvantage in the post-COVID-19 period.

Regarding testing, we disagree that it should be limited to areas affected by COVID-19 (5). The past few weeks have shown how dynamic the epidemiological situation is. We cannot take risks and expose transplanted patients to an unknown hazard. In the current setting, we would prefer to transplant patients who already developed an immunity against SARS CoV2, as they are likely protected against COVID-19 in the short term. We therefore advocate for serological testing of waitlisted patients and wide molecular testing of all patients immediately before transplantation.

However, one also needs to consider the limitations of serological testing, of which the specificity (cross-reactivity with other coronaviruses) and sensitivity still have to be determined.

Overall, we suggest the decision to halt transplantation activity must be integrated in a global public health perspective and taken only when absolutely necessary. Furthermore, we advocate for broad testing of donors and recipients, even in regions that are not COVID-19 hotspots. 

The COVID-19 outbreak in Italy: initial implications for organ transplantation programs

COVID-19 Information for Switzerland

Monthly analysis (COVID-19): key figures regarding organ transplantation in Switzerland

This article is protected by copyright. All rights reserved